Femasys Announces Notices of Intention to Grant for Two New European Patent Applications Covering Use of FemBloc Permanent Birth Control
Femasys Inc. (FEMY)
Company Research
Source: GlobeNewswire
ATLANTA, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Femasys Inc., (Nasdaq: FEMY), a leading biomedical innovator addressing significant unmet needs in women's health worldwide, with a broad portfolio of disruptive, accessible in-office therapeutic and diagnostic products, announces the European Patent Office (“EPO”) issued notices of Intention to Grant for two EU Patent Applications, EPO Application Nos. 24170531.8 and 18751753.7, which will have anticipated expirations in 2039 and 2038, respectively. Femasys plans to pursue additional patent applications to further strengthen its existing portfolio protecting FemBloc® permanent birth control, along with its other products, including FemaSeed®, FemVue®, FemCath® and FemCerv®. “The allowance of all requested claims for the two components of the non-surgical FemBloc permanent birth control marks a key milestone in extending protection for this revolutionary alternative to traditional surgical sterilization, which is costly, inconvenient, and
Show less
Read more
Impact Snapshot
Event Time:
FEMY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
FEMY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
FEMY alerts
High impacting Femasys Inc. news events
Weekly update
A roundup of the hottest topics
FEMY
News
- Femasys (NASDAQ:FEMY) was upgraded by analysts at <a style="font-weight:bold" href="https://www.wallstreetzen.com/newsletters/zen-ratings?ticker=FEMY&utm_campaign=getratings&utm_medium=online&utm_source=MarketBeat">Wall Street Zen</a> frMarketBeat
- Femasys (NASDAQ:FEMY) is now covered by analysts at Laidlaw. They set a "buy" rating and a $6.50 price target on the stock.MarketBeat
- Femasys GAAP EPS of -$0.10, revenue of $729M [Seeking Alpha]Seeking Alpha
- Femasys Announces Third Quarter Financial Results for 2025 [Yahoo! Finance]Yahoo! Finance
- Femasys Announces Third Quarter Financial Results for 2025GlobeNewswire
FEMY
Sec Filings
- 12/10/25 - Form EFFECT
- 12/4/25 - Form S-3/A
- 11/19/25 - Form 4
- FEMY's page on the SEC website